Molecular diagnostics in Melanoma: Current status and perspectives

Archives of Pathology and Laboratory Medicine

Volumn 135, Issue 7, 2011, Pages 860-869

  Dadras, Soheil S ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENETICS; HUMAN; MELANOMA; METABOLISM; MOLECULAR DIAGNOSIS; REVIEW; SKIN TUMOR;

HUMANS; MELANOMA; MOLECULAR DIAGNOSTIC TECHNIQUES; SKIN NEOPLASMS;

EID: 79960786239     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: None     Document Type: Review

References (96)

1. Nambiar S, Mirmohammadsadegh A, Hengge UR. Cutaneous melanoma: fishing with chips. Curr Mol Med. 2008;8(3):235-243. (Pubitemid 351982541)
2. McGinnis KS, Lessin SR, Elder DE, et al. Pathology review of cases presenting to a multidisciplinary pigmented lesion clinic. Arch Dermatol. 2002; 138(5):617-621.
3. Elder DE, Xu X. The approach to the patient with a difficult melanocyte lesion. Pathology. 2004;36(5):428-434. (Pubitemid 39273986)
4. Breslow A. Thickness, cross-sectional areas and depth of invasion in the prognosis of Cutaneous melanoma. Ann Surg. 1970,172(5):902-908.
5. Balch CM, Cershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27(36):6199-6206.
6. Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for Cutaneous melanoma. J Clin Oncol. 2001;19(16):3635-3648. (Pubitemid 32786276)
7. Blessing K, McLaren KM, McLean A, Davidson P. Thin malignant melanomas (less than 1.5 mm) with metastasis: a histological study and survival analysis. Hislopathology. 1990;17(5):389-395.
8. Ibrahim N, Haluska FG. Molecular pathogenesis of Cutaneous melanocytic neoplasms. Annu Rev Pathol. 2009;4:551-579.
9. Miller AJ, Mihm MC Jr. Melanoma. N Engl J Med. 2006;355(1):51-65.
10. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large Bcell lymphoma identified by gene expression profiling. Nature. 2000;403(6769): 503-511. (Pubitemid 30082188)
11. van de Vijver MJ, He YD, van't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002;347(25):1999-2009. (Pubitemid 35461656)
12. Paik S, Shak S, Tang C, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351(27): 2817-2826. (Pubitemid 40051905)
13. Haqq C, Nosrati M, Sudilovsky D, et al. The gene expression signatures of melanoma progression. Proc Natl Acad Sci USA. 2005;102(17):6092-6097. (Pubitemid 40594260)
14. Lewis TB, Robison JE, Bastien R, et al. Molecular classification of melanoma using real-time quantitative reverse transcriptase-polymerase chain reaction. Cancer. 2005; 104(8): 1678-1686. (Pubitemid 41437431)
15. Clark EA, Golub TR, Lander ES, Hynes RO. Genomic analysis of metastasis reveals an essential role for RhoC. Nature. 2000;406(6795):532-535. (Pubitemid 30625739)
16. Bittner M, Meltzer P, Chen Y, et al. Molecular classification of Cutaneous malignant melanoma by gene expression profiling. Nature. 2000;406(6795):536-540. (Pubitemid 30625740)
17. Duncan LM, Deeds J, Hunter J, et al. Down-regulation of the novel gene melastatin correlates with potential for melanoma metastasis. Cancer Res. 1998; 58(7):1515-1520. (Pubitemid 28193617)
18. Duncan LM, Deeds J, Cronin FE, et al. Melastatin expression and prognosis in Cutaneous malignant melanoma. J Clin Oncol. 2001;19(2):568-576. (Pubitemid 32112872)
19. Miller AJ, Du J, Rowan S, et al. Transcriptional regulation of the melanoma prognostic marker melastatin (TRPM1) by MITF in melanocytes and melanoma. Cancer Res. 2004;64(2):509-516. (Pubitemid 38120889)
20. Hammock L, Cohen C, Carlson G, et al. Chromogenic in situ hybridization analysis of melastatin mRNA expression in melanomas from American Joint Committee on Cancer stage I and II patients with recurrent melanoma. J Cutan Pathol. 2006;33(9):599-607. (Pubitemid 44370056)
21. Kashani-Sabet M, Rangel J, Torabian S, et al. A multi-marker assay to distinguish malignant melanomas from benign nevi. Proc Natl Acad Sci USA. 2009;106(15):6268-6272.
22. Koh SS, Opel ML, Wei JP, et al. Molecular classification of melanomas and nevi using gene expression microarray signatures and formalin-fixed and paraffinembedded tissue. Mod Pathol. 2009;22(4):538-546.
23. Van Gelder RN, von Zastrow ME, Yool A, et al. Amplified RNA synthesized from limited quantities of heterogeneous cDNA. Proc Natl Acad Sci USA. 1990,87(5): 1663-1667.
24. April C, Klotzle B, Royce T, et al. Whole-genome gene expression profiling of formalin-fixed, paraffin-embedded tissue samples. PloS One. 2009,4(12): e8162.doi:10.1371/journal.pone.0008162
25. Bastian BC, Olshen AB, LeBoit PE, Pinkel D. Classifying melanocytic tumors based on DNA copy number changes. Am J Pathol. 2003;163(5):1765-1770. (Pubitemid 37310008)
26. Bastian BC. Understanding the progression of melanocytic neoplasia using genomic analysis: from fields to cancer. Oncogene. 2003;22(20):3081-3086. (Pubitemid 36713759)
27. Kallioniemi A, Kallioniemi OP, Sudar D, et al. Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. Science. 1992; 258(5083):818-821.
28. Bauer J, Bastian BC. Distinguishing melanocytic nevi from melanoma by DNA copy number changes: comparative genomic hybridization as a research and diagnostic tool. Dermatol Ther. 2006;19(1):40-49.
29. Pinkel D, Segraves R, Sudar D, et al. High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays. Nat Genet. 1998;20(2):207-211. (Pubitemid 28455458)
30. Bastian BC, Wesselmann U, Pinkel D, Leboit PE. Molecular cytogenetic analysis of Spitz nevi shows clear differences to melanoma. J Invest Dermatol. 1999;113(6):1065-1069. (Pubitemid 30013354)
31. Harvell JD, Kohler S, Zhu S, et al. High-resolution array-based comparative genomic hybridization for distinguishing paraffin-embedded Spitz nevi and melanomas. Diagn Mol Pathol. 2004;13(1):22-25. (Pubitemid 38263879)
32. Harvell JD, Bastian BC, LeBoit PE. Persistent (recurrent) Spitz nevi: A histopathologic, immunohistochemical, and molecular pathologic study of 22 cases. Am J Surg Pathol. 2002;26(5):654-661. (Pubitemid 34438726)
33. Hantschke M, Bastian BC, LeBoit PE. Consumption of the epidermis: a diagnostic criterion for the differential diagnosis of melanoma and Spitz nevus. Am J Surg Pathol. 2004;28(12):1621-1625. (Pubitemid 39564968)
34. Zembowicz A, Carney JA, Mihm MC. Pigmented epithelioid melanocytoma: a low-grade melanocytic tumor with metastatic potential indistinguishable from animal-type melanoma and epithelioid blue nevus. Am J Surg Pathol. 2004; 28(1):31-40. (Pubitemid 38031618)
35. Zembowicz A, Knoepp SM, Bei T, et al. Loss of expression of proteinkinase a regulatory subunit 1 alpha in pigmented epithelioid melanocytoma but not in melanoma or other melanocytic lesions. Am J Surg Pathol. 2007;31(11): 1764-1775. (Pubitemid 350287576)
36. Mandal RV, Murali R, Lundquist KF, et al. Pigmented epithelioid melanocytoma: favorable outcome after 5-year follow-up. Am J Surg Pathol. 2009,33(12):1778-1782.
37. Curtin JA, FridlyandJ, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005;353(20):2135-2147. (Pubitemid 41653105)
38. Geissler EN, Ryan MA, Housman DE. The dominant-white spotting (W) locus of the mouse encodes the c-kit proto-oncogene. Cell. 1988;55(1): 185-192.
39. Chabot B, Stephenson DA, Chapman VM, Besmer P, Bernstein A. The proto-oncogene c-kit encoding a transmembrane tyrosine kinase receptor maps to the mouse W locus. Nature. 1988,335(6185):88-89.
40. Curtin JA, Busam K, Pinkel D, Bastian BC. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol. 2006;24(26):4340-4346. (Pubitemid 46630793)
41. Kim KB, Eton O, Davis DW, et al. Phase II trial of imatinib mesylate in patients with metastatic melanoma. Br J Cancer. 2008;99(5):734-740.
42. Balaban G, Herlyn M, Guerry D IV, et al. Cytogenetics of human malignant melanoma and premalignant lesions. Cancer Genet Cytogenet. 1984; 11(4):429-439. (Pubitemid 14107795)
43. Bastian BC, LeBoit PE, Hamm H, Brocker EB, Pinkel D. Chromosomal gains and losses in primary Cutaneous melanomas detected by comparative genomic hybridization. Cancer Res. 1998;58(10):2170-2175. (Pubitemid 28232904)
44. Cowan JM, Halaban R, Francke U. Cytogenetic analysis of melanocytes from premalignant nevi and melanomas. I Natl Cancer Inst. 1988;80(14):1159-1164.
45. Limon J, Dal Cin P, Sait SN, Karakousis C, Sandberg AA. Chromosome changes in metastatic human melanoma. Cancer Genet Cytogenet. 1988;30(2): 201-211.
46. Parmiter AH, Nowell PC. The cytogenetics of human malignant melanoma and premalignant lesions. Cancer Treat Res. 1988;43:47-61.
47. Gerami P, Wass A, Mafee M, Fang Y, Pulitzer MP, Busam KJ. Fluorescence in situ hybridization for distinguishing nevoid melanomas from mitotically active nevi. Am J Surg Pathol. 2009;33(12):1783-1788.
48. Morey AL, Murali R, McCarthy SW, Mann GJ, Scolyer RA. Diagnosis of Cutaneous melanocytic tumours by four-colour fluorescence in situ hybridisation. Pathology. 2009;41(4):383-387.
49. Piepkorn M. The diagnostic reproducibility of melanocytic dysplasia. Arch Dermatol. 1998;134(8):1037-1039.
50. Wakely SL, Baxendine-Jones JA, Gallagher PJ, Mullee M, Pickering R. Aberrant diagnoses by individual surgical pathologists. Am J Surg Pathol. 1998; 22(1):77-82. (Pubitemid 28016755)
51. Omholt K, Platz A, Kanter L, Ringborg U, Hansson J. NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression. Clin Cancer Res. 2003;9(17):6483-6488. (Pubitemid 38031837)
52. Pollock PM, Harper UL, Hansen KS, et al. High frequency of BRAF mutations in nevi. Nat Genet. 2003;33(1):19-20. (Pubitemid 36068675)
53. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949-954. (Pubitemid 34716871)
54. Demunter A, Stas M, Degreef H, De Wolf-Peeters C, van den Oord JJ. Analysis of N- and K-ras mutations in the distinctive tumor progression phases of melanoma. J Invest Dermatol. 2001;117(6):1483-1489. (Pubitemid 34032777)
55. Papp T, Pemsel H, Zimmermann R, et al. Mutational analysis of the N-ras, p53, p16INK4a, CDK4, and MC1R genes in human congenital melanocytic naevi. J Med Genet. 1999;36(8):610-614. (Pubitemid 29368901)
56. van Dijk MC, Bernsen MR, Ruiter DJ. Analysis of mutations in B-RAF, NRAS, and H-RAS genes in the differential diagnosis of Spitz nevus and spitzoid melanoma. Am J Surg Pathol. 2005;29(9):1145-1151. (Pubitemid 41232985)
57. Bauer J, Curtin JA, Pinkel D, Bastian BC. Congenital melanocytic nevi frequently harbor NRAS mutations but no BRAF mutations. J Invest Dermatol. 2007;127(1 ):179-182. (Pubitemid 46005676)
58. Pollock PM, Meltzer PS. A genome-based strategy uncovers frequent BRAF mutations in melanoma. Cancer Cell. 2002;2(1):5-7. (Pubitemid 41043982)
59. Viros A, Fridlyand J, Bauer J, et al. Improving melanoma classification by integrating genetic and morphologic features. PLoS Med. 2008;5(6):e120. doi:10.1371/journal.pmed.0050120. (Pubitemid 351919116)
60. Shinozaki M, Fujimoto A, Morton DL, Hoon DS. Incidence of BRAF oncogene mutation and clinical relevance for primary Cutaneous melanomas. Clin Cancer Res. 2004;10(5):1753-1757. (Pubitemid 38435567)
61. Maldonado JL, Fridlyand J, Patel H, et al. Determinants of BRAF mutations in primary melanomas. ; Natl Cancer Inst. 2003;95(24):1878-1890.
62. Chang DZ, Panageas KS, Osman I, et al. Clinical significance of BRAF mutations in metastatic melanoma. J Transl Med. 2004;2(1):46.
63. Kannengiesser C, Spatz A, Michiels S, et al. Gene expression signature associated with BRAF mutations in human primary Cutaneous melanomas. Mol Oncol. 2008;1(4):425-430.
64. Inoue T, Nabeshima K, Kataoka H, Koono M. Feasibility of archival nonbuffered formalin-fixed and paraffin-embedded tissues for PCR amplification: an analysis of resected gastric carcinoma. Pathol Int. 1996;46(12):997-1004.
65. Cronin M, Pho M, Dutta D, et al. Measurement of gene expression in archival paraffin-embedded tissues: development and performance of a 92-gene reverse transcriptase-polymerase chain reaction assay. Am J Pathol. 2004;164(1): 35-12.
66. Masuda N, Ohnishi T, Kawamoto S, Monden M, Okubo K. Analysis of chemical modification of RNA from formalin-fixed samples and optimization of molecular biology applications for such samples. Nucleic Acids Res. 1999; 27(22):4436-4443. (Pubitemid 29533185)
67. Finke J, Fritzen R, Ternes P, Lange W, Dolken G. An improved strategy and a useful housekeeping gene for RNA analysis from formalin-fixed, paraffinembedded tissues by PCR. Biotechniques. 1993;14(3):448-453. (Pubitemid 23086133)
68. Krafft AE, Duncan BW, Bijwaard KE, Taubenberger JK, Lichy JH. Optimization of the isolation and amplification of RNA from formalin-fixed, paraffin-embedded tissue: the Armed Forces Institute of Pathology experience and literature review. Mol Diagn. 1997;2(3):217-230. (Pubitemid 127734948)
69. Ma XJ, Patel R, Wang X, et al. Molecular classification of human cancers using a 92-gene real-time quantitative polymerase chain reaction assay. Arch Pathol Lab Med. 2006;130(4):465-473
70. Byers R, Roebuck J, Sakhinia E, Hoyland J. PolyA PCR amplification of cDNA from RNA extracted from formalin-fixed paraffin-embedded tissue. Diagn Mol Pathol. 2004;13(3):144-150. (Pubitemid 39121739)
71. Lehmann U, Kreipe H. Real-time PCR analysis of DNA and RNA extracted from formalin-fixed and paraffin-embedded biopsies. Methods. 2001;25(4):409-418. (Pubitemid 34164013)
72. Antonov J, Goldstein DR, Oberli A, et al. Reliable gene expression measurements from degraded RNA by quantitative real-time PCR depend on short amplicons and a proper normalization. Lab Invest. 2005;85(8):1040-1050. (Pubitemid 41486428)
73. Doleshal M, Magotra AA, Choudhury B, et al. Evaluation and validation of total RNA extraction methods for microRNA expression analyses in formalinfixed, paraffin-embedded tissues. J Mol Diagn. 2008;10(3):203-211. (Pubitemid 351692162)
74. Nelson PT, Baldwin DA, Scearce LM, et al. Microarray-based, highthroughput gene expression profiling of microRNAs. Nat Methods. 2004;1(2): 155-161.
75. Ma Z, Lui WO, Fire A, Dadras SS. Profiling and discovery of novel miRNAs from formalin-fixed, paraffin-embedded melanoma and nodal specimens. J Mol Diagn. 2009;11 (5):420-429.
76. Glud M, Klausen M, Gniadecki R, et al. MicroRNA expression in melanocyte nevi: the usefulness of formalin-fixed, paraffin-embedded material for miRNA microarray profiling. J Invest Dermatol. 2009;129(5):1219-1224.
77. Liu A, Tetzlaff MT, Vanbelle P, et al. MicroRNA expression profiling outperforms mRNA expression profiling in formalin-fixed paraffin-embedded tissues. IntJ Clin Exp Pathol. 2009;2(6):519-527.
78. Barrel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281-297.
79. Esquela-Kerscher A, Slack FJ. Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer. 2006;6(4):259-269.
80. Calin GA, Dumitru CD, Shimizu M, et al. Frequent deletions and downregulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA. 2002;99(24):15524-15529. (Pubitemid 35403967)
81. Calin GA, Ferracin M, Cimmino A, et al. A microRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med. 2005,353(17):1793-1801. (Pubitemid 41549891)
82. Kluiver J , Poppema S, de Jong D, et al. BIC and miR-155 are highly expressed in Hodgkin, primary mediastinal and diffuse large B cell lymphomas. J Pathol. 2005;207(2):243-249. (Pubitemid 41404155)
83. Calin GA, Liu CG, Sevignani C, et al. MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc Natl Acad Sci USA. 2004;101 (32):11755-11760. (Pubitemid 39095368)
84. Takamizawa J, Konishi H, Yanagisawa K, et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res. 2004;64(11):3753-3756. (Pubitemid 38697282)
85. Michael MZ, O'Connor SM, van Hoist Pellekaan NG, Young GP, James RJ. Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol Cancer Res. 2003;1(12):882-891. (Pubitemid 37288707)
86. Chan JA, Krichevsky AM, Kosik KS. MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res. 2005;65(14):6029-6033. (Pubitemid 40994386)
87. Lui WO, Pourmand N, Patterson BK, Fire A. Patterns of known and novel small RNAs in human cervical cancer. Cancer Res. 2007;67(13):6031-6043. (Pubitemid 47037482)
88. Glud M, Klausen M, Gniadecki R, et al. MicroRNA expression in melanocyte nevi: the usefulness of formalin-fixed, paraffin-embedded material for miRNA microarray profiling. I Invest Dermatol. 2009;129(5):1219-1224.
89. Lau NC, Lim LP, Weinstein EG, Bartel DP. An abundant class of tiny RNAs with probable regulatory roles in Caenorhabditis elegans. Science. 2001; 294(5543):858-862. (Pubitemid 33032104)
90. Berezikov E, Cuppen E, Plasterk RH. Approaches to microRNA discovery. Nat Genet. 2006;38(suppl):S2-S7.
91. Li J, Smyth P, Flavin R, et al. Comparison of miRNA expression patterns using total RNA extracted from matched samples of formalin-fixed paraffinembedded (FFPE) cells and snap frozen cells. BMC Biotechnol. 2007;7:36.
92. Schultz J, Lorenz P, Gross G, Ibrahim S, Kunz M. MicroRNA let-7b targets important cell cycle molecules in malignant melanoma cells and interferes with anchorage-independent growth. Cell Res. 2008;18(5):549-557. (Pubitemid 351630945)
93. Muller DW, Bosserhoff AK. Integrin beta 3 expression is regulated by let- 7a miRNA in malignant melanoma. Oncogene. 2008;27(52):6698-6706.
94. Garraway LA, Widlund HR, Rubin MA, et al. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature. 2005;436(7047):117-122. (Pubitemid 40966196)
95. Ozsolak F, Poling LL, Wang Z, et al. Chromatin structure analyses identify miRNA promoters. Genes Dev. 2008;22(22):3172-3183.
96. Parameswaran P, Jalili R, Tao L, et al. A pyrosequencing-tailored nucleotide barcode design unveils opportunities for large-scale sample multiplexing. Nucleic Acids Res. 2007;35(19):e130 doi:10.1093/nar/gkm760. (Pubitemid 350111638)